The cumulative risk of cardiorenal toxicity associated with contemporary oncologic therapies—including HER2-targeted agents, anthracyclines, VEGF inhibitors, cyclin-dependent kinase 6 (CDK6) inhibitors, and hormonal therapies—stems from their capacity to exacerbate preexisting cardiovascular and renal dysfunction [115]. The gene discussed is CDK6; the disease is Abnormal renal physiology.